Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry
Arturo Cesaro, Felice Gragnano, Paolo Calabrò, Elisabetta Moscarella, Francesco Santelli, Fabio Fimiani, Giuseppe Patti, Ilaria Cavallari, Emilia Antonucci, Plinio Cirillo, Pasquale Pignatelli, Gualtiero Palareti, Francesco Pelliccia, Eduardo Bossone, Vittorio Pengo, Paolo Gresele, Rossella Marcucci, Alessandra Schiavo, Andrea Vergara, Daniele Pastori, Danilo Menichelli, Guido Grossi, Luigi Di Serafino, Vittorio Taglialatela, Maurizio Del Pinto, Giuseppe Gugliemini
Topics & Concepts
MedicineTicagrelorRivaroxabanMaceAntithromboticMyocardial infarctionCohortInternal medicineHazard ratioAcute coronary syndromeStroke (engine)Adverse effectIncidence (geometry)Emergency medicineWarfarinPercutaneous coronary interventionAtrial fibrillationConfidence intervalPhysicsEngineeringMechanical engineeringOpticsAntiplatelet Therapy and Cardiovascular DiseasesAtrial Fibrillation Management and OutcomesAcute Myocardial Infarction Research